Tmunity raises $10M for T cells

Tmunity Therapeutics Inc. (Philadelphia, Penn.) raised $10 million in a venture round from Penn Medicine and Lilly Asia Ventures to develop engineered T cell immunotherapies for cancer and infectious and autoimmune diseases.

Tmunity said it is developing T cell receptor ( TCR) engineered T cells, Treg cells, and universal engineered T cell platforms that control T cell activation and direction in vivo. The company also is developing technologies to activate, expand and genetically engineer T cells from peripheral blood, cord blood and tumors. ...